Thought this was interesting: We hold five U.S.
Post# of 36537
(Total Views: 373)
Posted On: 07/23/2020 6:05:21 PM
Re: Paul Jackson #18929
Thought this was interesting:
We hold five U.S. patents and one patent in Japan. The U.S. patent numbers are7,935,350 (expiring Novemeber 3, 2022), 8,748,130 (expiring on December 10, 2025), 8889143 (expiring on May 18, 2026), 928945 (expiring on September 22, 2027), 8,815,249 (expiring on February 26, 2026). Japan patent number is 5707326 (expiring September 1, 2029). These patents cover:
Compositions and Methods Related to Ii Technology•
Ii hybrid peptides used for the enhancement of antigen presentation•
Constructs for the expression of Ii-Key/antigen epitope fusion peptides•
Hybrid Ii-Key/antigen epitope fusion peptides•
Methods for inhibiting Ii expression
We also have U.S. patents on the Ii-Key technology have expired, we are in discussions with third parties to extend the patent coverage of the Ii-Key technology for cancer immunotherapy.[/b
Is it bad that patent for ii key for cancer immunotherapy has expired.
Also above
Compositions and Methods Related to Ii Technology patent seems to expire in Nov 2022. Not that far out...
We hold five U.S. patents and one patent in Japan. The U.S. patent numbers are7,935,350 (expiring Novemeber 3, 2022), 8,748,130 (expiring on December 10, 2025), 8889143 (expiring on May 18, 2026), 928945 (expiring on September 22, 2027), 8,815,249 (expiring on February 26, 2026). Japan patent number is 5707326 (expiring September 1, 2029). These patents cover:
Compositions and Methods Related to Ii Technology•
Ii hybrid peptides used for the enhancement of antigen presentation•
Constructs for the expression of Ii-Key/antigen epitope fusion peptides•
Hybrid Ii-Key/antigen epitope fusion peptides•
Methods for inhibiting Ii expression
We also have U.S. patents on the Ii-Key technology have expired, we are in discussions with third parties to extend the patent coverage of the Ii-Key technology for cancer immunotherapy.[/b
Is it bad that patent for ii key for cancer immunotherapy has expired.
Also above
Compositions and Methods Related to Ii Technology patent seems to expire in Nov 2022. Not that far out...
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼